Evidence Level Notice
GPC3-directed CAR-T therapy currently has no regulatory approval (FDA, EMA, or NMPA) in any jurisdiction. All patient access is exclusively through clinical trials. Results from early-phase studies may not be reproducible in routine clinical practice. This page describes investigational approaches, not established treatments.
GPC3-Targeted CAR-T Cell Therapy: Investigational Overview for Liver Cancer
An independent clinical reference for GPC3-directed CAR-T therapy — an investigational approach for Hepatocellular Carcinoma (HCC) and other GPC3-positive malignancies.
What is GPC3?
GPC3 (Glypican-3) is a glycosylphosphatidylinositol (GPI)-anchored proteoglycan that plays a role in cell growth and differentiation. During normal development, GPC3 is expressed in fetal liver and other embryonic tissues, but in healthy adult tissues, GPC3 expression is virtually absent — with the exception of limited expression in certain normal tissues (e.g., placenta, mesothelial cells).
Critical Distinction from Claudin18.2: Unlike Claudin18.2 (which is expressed in normal gastric mucosa and carries on-target, off-tumor toxicity risk), GPC3's near-complete absence in healthy adult tissues makes it a theoretically safer target from an immunotoxicity standpoint. However, this biological advantage comes with its own challenges: GPC3 expression in hepatocellular carcinoma (HCC) can be heterogeneous, and not all tumors express sufficient GPC3 to be targetable.
For a detailed explanation of how CAR-T cells are engineered to target specific antigens, please refer to our CAR-T Cell Therapy Hub →
Target Malignancies
GPC3-directed CAR-T therapy is under investigation for malignancies with high GPC3 expression:
- Hepatocellular Carcinoma (HCC) — primary focus of clinical development (GPC3 is overexpressed in approximately 70–80% of HCC cases)
- Other GPC3-Positive Tumors — emerging investigational target (e.g., some germ cell tumors, hepatoblastoma; early-phase)
Testing Requirement: GPC3 expression must be confirmed by immunohistochemistry (IHC) testing. Patient eligibility for clinical trials is contingent on documented GPC3 positivity (thresholds vary by trial, typically ≥20–30% of tumor cells).
Investigational Constructs in Active Clinical Trials
Unlike CD19 and BCMA, no GPC3-targeted CAR-T product has received regulatory approval. The table below lists investigational constructs in active clinical development.
| Construct / Code Name | Developer / Sponsor | Phase | Trial Location | Registry |
|---|---|---|---|---|
| GPC3 CAR-T (IASO Bio) | IASO Bio | Phase 1/2 | China | Search → |
| GPC3 CAR-T (academic/institutional) | Multiple academic centers | Phase 1 | China, other regions | Search → |
| Additional constructs | Multiple sponsors | Phase 1 | Global | Search → |
Note: Clinical trial availability, enrollment status, and eligibility criteria change frequently. The links above direct to live ClinicalTrials.gov search results for "GPC3 CAR-T." Always verify current trial status directly with the sponsor or registry.
Level of Evidence — Explicit Comparison
GPC3 CAR-T is at an earlier stage of clinical validation than CD19, BCMA, and even Claudin18.2.
| Target | Evidence Maturity | Regulatory Status | Data Horizon |
|---|---|---|---|
| CD19 | Level 1 Phase III, 8+ years post-marketing |
FDA/EMA/NMPA approved (5+ products) |
2017–present |
| BCMA | Level 1 Phase III, 3+ years post-marketing |
FDA/EMA approved (2 products) |
2021–present |
| Claudin18.2 | Level 2–3 Phase 1/2, single-arm |
No regulatory approval | 2019–present |
| GPC3 | Level 2–3 Phase 1/2, very small cohorts |
No regulatory approval | 2020–present (early-phase only) |
What this means clinically:
- GPC3 CAR-T data come primarily from Phase 1 dose-escalation studies with very limited patient numbers (typically <20–30 patients per trial).
- There are no randomized Phase III trials comparing GPC3 CAR-T to standard-of-care.
- Long-term safety and efficacy data beyond 1–2 years are not yet available.
- Results observed in highly selected trial populations may not generalize to broader clinical practice.
International Access Limitations — Honest Assessment
Access to GPC3 CAR-T clinical trials is not guaranteed and is subject to strict eligibility criteria:
- Molecular Eligibility: Patients must have documented GPC3 expression (typically ≥20–30% of tumor cells by IHC, though thresholds vary by trial).
- Prior Therapy Requirements: Most trials require patients to have progressed on or be ineligible for standard therapies (surgery, locoregional therapy, systemic therapy including sorafenib/lenvatinib, immunotherapy).
- Liver Function Constraints: Many HCC patients have underlying cirrhosis or compromised liver function. Trials typically require adequate hepatic function (e.g., Child-Pugh A or early B), which may exclude patients with advanced liver disease.
- Performance Status: Patients must meet strict ECOG performance status criteria (typically ECOG 0–1), excluding those with significant comorbidities.
- Geographic and Logistical Constraints: Trials are conducted at specific sites (predominantly in China). International patients must be able to travel to and remain near the trial site for the duration of treatment and follow-up (often 1–3 months minimum).
- No Guarantee of Enrollment: Meeting eligibility criteria does not guarantee acceptance. Trial sites have limited capacity and may prioritize patients based on specific scientific objectives.
For patients considering international clinical trials: Our platform can facilitate secure transfer of medical records for trial screening, but we cannot pre-approve eligibility or guarantee enrollment. All decisions are made by the trial investigators based on their specific protocol requirements. Request an Information-Based Case Review →